Korean J Urol.  2010 Oct;51(10):704-708.

The Different Reduction Rate of Prostate-Specific Antigen in Dutasteride and Finasteride

• Choi YH
• Cho SY
• Cho IR

Abstract

PURPOSE
To compare and analyze the therapeutic effects and changes in the prostate-specific antigen (PSA) level with treatment with finasteride or dutasteride for benign prostatic hyperplasia (BPH) for 1 year.
MATERIALS AND METHODS
We retrospectively investigated patients who suffered from BPH for 1 year between January 2005 and December 2008. For treatment groups, we divided the patients into two groups: one was treated with alfuzosin and finasteride and the other was treated with alfuzosin and dutasteride. At the beginning of treatment, the patients underwent transrectal ultrasonography and measurement of urine flow rate, residual urine volume, PSA, and International Prostate Symptom Score (IPSS). Patients with diseases affecting urinary function were excluded. We not only analyzed the data at the time of initial treatment, but also after 1 year of treatment. A total of 219 patients were able to be evaluated for 1 year.
RESULTS
Both finasteride and dutasteride reduced PSA and prostate volume significantly. The comparison between groups showed a more significant reduction of PSA (p=0.020) and prostate volume (p=0.052) in the dutasteride group. Other parameters did not differ significantly between the groups.
CONCLUSIONS
5-alpha Reductase inhibitors for BPH treatment reduced PSA and prostate volume significantly when the patients were treated for 1 year. Administration of dutasteride is considered to be more effective in reducing PSA and prostate volume. Therefore, dutasteride should not be considered equivalent to finasteride in the reduction rate of PSA. The intensity of dutasteride must be reevaluated in comparison with finasteride.

Keyword

Dutasteride; Finasteride; Prostate-specific antigen; Prostatic hyperplasia

MeSH Terms

5-alpha Reductase Inhibitors
Azasteroids
Finasteride
Humans
Prostate
Prostate-Specific Antigen
Prostatic Hyperplasia
Quinazolines
Retrospective Studies
Dutasteride
5-alpha Reductase Inhibitors
Azasteroids
Finasteride
Prostate-Specific Antigen
Quinazolines

Reference

1. Thorpe A, Neal D. Benign prostatic hyperplasia. Lancet. 2003. 361:1359–1367.

2. Holtgrewe HL, Mebust WK, Dowd JB, Cockett AT, Peters PC, Proctor C. Transurethral prostatectomy: practice aspects of the dominant operation in American urology. J Urol. 1989. 141:248–253.

3. Iehle C, Delos S, Guirou O, Tate R, Raynaud JP, Martin PM. Human prostatic steroid 5 alpha-reductase isoforms--a comparative study of selective inhibitors. J Steroid Biochem Mol Biol. 1995. 54:273–279.

4. Titus MA, Gregory CW, Ford OH 3rd, Schell MJ, Maygarden SJ, Mohler JL. Steroid 5alpha-reductase isozymes I and II in recurrent prostate cancer. Clin Cancer Res. 2005. 11:4365–4371.

5. Marihart S, Harik M, Djavan B. Dutasteride: a review of current data on a novel dual inhibitor of 5alpha reductase. Rev Urol. 2005. 7:203–210.

6. Finasteride Study Group. Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. Prostate. 1993. 22:291–299.

7. Debruyne F, Barkin J, van Erps P, Reis M, Tammela TL, Roehrborn C. Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. Eur Urol. 2004. 46:488–494.

8. McConnell JD, Wilson JD, George FW, Geller J, Pappas F, Stoner E. Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. J Clin Endocrinol Metab. 1992. 74:505–508.

9. Span PN, Völler MC, Smals AG, Sweep FG, Schalken JA, Feneley MR, et al. Selectivity of finasteride as an in vivo inhibitor of 5 alpha-reductase isozyme enzymatic activity in the human prostate. J Urol. 1999. 161:332–337.

10. Andriole GL, Humphrey P, Ray P, Gleave ME, Trachtenberg J, Thomas LN, et al. Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer. J Urol. 2004. 172:915–919.

11. McConnell JD, Bruskewitz R, Walsh P, Andriole G, Lieber M, Holtgrewe HL, et al. Finasteride Long-Term Efficacy and Safety Study Group. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med. 1998. 338:557–563.

12. Fenter TC, Davis EA, Shah MB, Lin PJ. Dutasteride vs finasteride: assessment of differences in acute urinary retention rates and surgical risk outcomes in an elderly population aged > or =65 years. Am J Manag Care. 2008. 14:5 Suppl 2. S154–S159.

13. Naslund MJ, Miner M. A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate. Clin Ther. 2007. 29:17–25.

14. Roehrborn CG, Lukkarinen O, Mark S, Siami P, Ramsdell J, Zinner N. Long-term sustained improvement in symptoms of benign prostatic hyperplasia with the dual 5alpha-reductase inhibitor dutasteride: results of 4-year studies. BJU Int. 2005. 96:572–577.

15. O'Leary MP, Roehrborn C, Andriole G, Nickel C, Boyle P, Höfner K. Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5alpha-reductase inhibitor. BJU Int. 2003. 92:262–266.

16. Issa MM, Runken MC, Grogg AL, Shah MB. A large retrospective analysis of acute urinary retention and prostate-related surgery in BPH patients treated with 5-alpha reductase inhibitors: dutasteride versus finasteride. Am J Manag Care. 2007. 13:Suppl 1. S10–S16.

17. Milam D, Oesterling JE, Roehrborn CG, Auerbach S, Padley RJ. Serial prostate-specific antigen measurements in patients with clinical benign prostatic hyperplasia enrolled in a randomized, double-blinded, placebo-controlled study with terazosin. J Urol. 1995. 153:Suppl. 396A.

18. Brown JA, Peterson DD, Lieber MK, Oesterling JE. Terazosin and finasteride both lower the serum prostate-specific antigen (PSA) level in men with benign prostatic hyperplasia (BPH). J Urol. 1996. 155:Suppl. 424A.

19. Bozeman CB, Carver BS, Eastham JA, Venable DD. Treatment of chronic prostatitis lowers serum prostate specific antigen. J Urol. 2002. 167:1723–1726.

20. Potts JM. Prospective identification of National Institutes of Health category Category IV prostatitis in men with elevated prostate specific antigen. J Urol. 2000. 164:1550–1553.

21. Fowke JH, Motley SS, Smith JA Jr, Cookson MS, Concepcion R, Chang SS, et al. Association of nonsteroidal anti-inflammatory drugs, prostate specific antigen and prostate volume. J Urol. 2009. 181:2064–2070.

22. Guess HA, Heyse JF, Gormley GJ, Stoner E, Oesterling JE. Effect of finasteride on serum PSA concentration in men with benign prostatic hyperplasia. Results from the North American phase III clinical trial. Urol Clin North Am. 1993. 20:627–636.

23. Espana F, Martinez M, Royo M, Estelles A, Alapont JM, Navarro S, et al. Changes in molecular forms of prostate-specific antigen during treatment with finasteride. BJU Int. 2002. 90:672–677.

24. Hong JE, Hong SJ. Changes in prostate volume, transitional zone volume and PSA after cessation of the finasteride. Korean J Urol. 1999. 40:1519–1524.

25. Brawer MK, Lin DW, Williford WO, Jones K, Lepor H. Effect of finasteride and/or terazosin on serum PSA: results of VA Cooperative Study #359. Prostate. 1999. 39:234–239.

26. Andriole GL, Guess HA, Epstein JI, Wise H, Kadmon D, Crawford ED, et al. PLESS Study Group. Proscar Long-term Efficacy and Safety Study. Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. Urology. 1998. 52:195–201.

27. Andriole GL, Marberger M, Roehrborn CG. Clinical usefulness of serum prostate specific antigen for the detection of prostate cancer is preserved in men receiving the dual 5alpha-reductase inhibitor dutasteride. J Urol. 2006. 175:1657–1662.

28. Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med. 2010. 362:1192–1202.